Response by de Ridder et al to Letter Regarding Article, “PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2) Results of a Randomized, Double-Blind Placebo-Controlled Clinical Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We thank Drs Noubiap and Kamtchum-Tatuene for their comments on our article. They express their concerns about the safety of short-term treatment with high-dose paracetamol, question whether the high dose of paracetamol used in PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2) leads to a larger temperature reduction than a standard dose, and consider a new, larger, clinical trial of fever prevention in stroke futile. Their concerns can fortunately be refuted.
Over the years, we conducted several trials with paracetamol in patients with acute stroke. During these trials, we monitored liver function and infection parameters and found no increased rate of clinically relevant liver disturbances or increased infection parameters.1,2 These studies were performed in relatively unselected populations, representative of the usual patient with stroke. Based on these …